BackTable Tumor Board

What if there was an effective treatment for hepatocellular carcinoma (HCC) that combines systemic immunotherapy with liver-directed therapies like Y90? In this final episode of the BackTable 2026 HCC Creator Weekend™, Dr. Lingling Du, Dr. A. Craig Lockhart, and Dr. Jon Mizrahi discuss what's next for the HCC landscape as it continues to evolve. What new targets and strategies are set to shape clinical practice in the near future? Listen to the full episode here: na2.hubs.ly/H05shR20 #HepatocellularCarcinoma #HCC #Immunotherapy #TargetedTherapy #ONC59

What comes after first-line immunotherapy in advanced hepatocellular carcinoma (HCC)? From tyrosine kinase inhibitor dosing to the limited role of next-generation sequencing, the following episode of the BackTable 2026 HCC Creator Weekend™ breaks down the complexities of second-line decision-making. Listen here: na2.hubs.ly/H05jh2J0 #HCC #MedicalOncology #SecondLine #HCCCreatorWeekend #ONC58

How did a single trial in 2020 overturn 10 years of standard care in #HCC? On TB57, Dr. John Rahi, Dr. Craig Lockhart, and Dr. Lingling Du review the shift from TKIs to IO combinations. Check out the long-term survival "tails" that are changing the prognosis for advanced liver cancer. Listen here: na2.hubs.ly/H05bp2r0 #Oncology #LiverCancer #Immunotherapy #ONC57

Creator Weekend in Nashville is in the books! Four new episodes recorded, big conversations captured, and a weekend focused on advancing NMIBC care through multidisciplinary collaboration. 🎙️ Topics included: • Intravesical therapy clinic models • Shared decision-making • Risk stratification • Toxicity triage and supportive care Excited to share these episodes soon. #BTCreatorWeekend #UrologicOncology #BladderCancer

The BackTable App brings together expert conversations, courses, case discussions, and more - all in one place! Already listening? Download the BackTable App: na2.hubs.ly/H0552Rc0 #MedEd #ClinicalLearning

Explore how tumor biomarkers enable personalized breast cancer treatment while helping reduce financial toxicity in precision medicine. In this new episode of BackTable Tumor Board, Dr. Jessica Treviño Jones and Dr. Lindsay Peterson cover how genomic testing, technological advances, current research, and patient education inform treatment selection for both early-stage and metastatic breast cancer. Tune in for the full episode here: na2.hubs.ly/H050Wrn0 Or visit na2.hubs.ly/H050Wk30 #BreastCancer #MetastaticBreastCancer #MedicalOncology #PrecisionMedicine #Biomarkers #ONC56

How will the latest colorectal cancer data change practice? At the 2026 ASCO GI Symposium in San Francisco, trials like BREAKWATER, COMMIT, ATOMIC, and CHALLENGE are redefining treatment strategies. On the latest BackTable Tumor Board episode, Dr. Shruti Patel and Dr. Jun Gong break down what these trials reveal about where colorectal cancer management is headed next. Listen here: na2.hubs.ly/H04TSXl0 or visit na2.hubs.ly/H04TRSn0 #ColorectalCancer #2026GIASCO #MedicalOncology #Phase3ClinicalTrials #ONC55

You know BackTable. Now make it yours. Inside the app: - A For You feed built around your specialty - Search across clinical topics - Real clinical case discussions - And more Download the BackTable App: na2.hubs.ly/H04Q49m0

A patient with just two progressing lesions. Do you start systemic therapy or target locally? With the examples of a few patient cases, Drs. Ryan Funk and Dustin Boothe break down how they approach isolated progression (treat locally with radiation) and widespread progression (escalate to radiopharmaceuticals like Pluvicto) while limiting patient toxicity. Another aspect to consider is looking at the whole patient and their quality of life when managing the systemic therapy space. Watch the full episode: backtable.com/shows/tumor-bo… This podcast is supported by Varian Theranostics. #Radiopharmaceuticals #RadiationOncology #Theranostics #Oncology #TB50

“You need to be curious. You need to be ambitious and not be afraid to think critically.” - Dr. Riad Salem Dr. Riad Salem joins Dr. Tyler Sandow and Dr. Juan Gimenez for a conversation around the moments, decisions, and lessons that shaped his career and the field of Interventional Oncology. 🎧 Available now, only in the BackTable App Download now and listen - na2.hubs.ly/H04Ms4Y0 #VI632 #Y90 #InterventionalRadiology #HCC #InterventionalOncology

Jun Gong and Tyler Stewart discuss how KEYNOTE-B15 and KEYNOTE-905 are redefining bladder cancer care. With EVP becoming the first non-platinum regimen to outperform cisplatin, the curative window for MIBC is shifting.\ Listen here: na2.hubs.ly/H04LwjY0 #BladderCancer #Oncology #ONC54 #ASCOGU26 #MedTwitter

You’ve listened to BackTable. Now experience it in a whole new way. Inside the app: - A For You feed personalized to your specialty - Clinical search across real-world topics - Real cases from practicing physicians The next chapter of BackTable starts here! Download the BackTable App: na2.hubs.ly/H04Hq2w0

Dr. Ryan Funk breaks down how radiopharmaceutical therapies are reshaping the radiation oncologist’s role in community practice—from broader toxicity management to deeper multidisciplinary collaboration. As radiopharmaceuticals move earlier in treatment pathways, radiation oncologists are increasingly co-managing longitudinal patient care in addition to delivering targeted therapy. Watch the full episode on the BackTable app: backtable.com/shows/tumor-bo… This podcast is supported by Varian Theranostics. #Radiopharmaceuticals #RadiationOncology #Theranostics #OncologyCare #VarianTheranostics #TB50

ADCs are redefining the breast cancer landscape, but with great efficacy comes the need for better monitoring. In our latest episode, Dr. Kate Baker & Dr. Sara Nunnery break down HER2-low vs. Ultralow, ILD risk & steroid protocols, and next-gen targets. Listen now: na2.hubs.ly/H04t2nR0 #ONC52 #BreastCancer #HER2 #Oncology #ADCs

That’s a wrap on HCC Creator Weekend in New Orleans! We sat down with leading experts from across the country to record new episodes on hepatocellular carcinoma management, emerging therapies, and multidisciplinary care. 🎙️ New episodes and bonus content will be dropping over the next several weeks in the BackTable app: na2.hubs.ly/H04hpTL0 Stay tuned. #HCC #LiverCancer #Oncology #TumorBoard #MedOnc #BackTable

@CedarsSinai oncologists Karen Reckamp and Jun Gong recently sat down with host Venkatesh Krishnasamy to discuss the evolving role of liquid biopsy and circulating tumor DNA (ctDNA) in cancer care. From biomarker-driven treatment decisions in lung cancer to emerging applications in colorectal cancer, these conversations explore how ctDNA is shaping the future of precision oncology. 📖 Read the article: cedars-sinai.org/newsroom/backt… #Oncology #LiquidBiopsy #ctDNA #CancerResearch #TumorBoard #MedOnc #ONC36

Radiopharmaceuticals are gaining momentum in modern oncology and rapidly transforming cancer care. How do you actually bring them into practice? In this episode of BackTable Tumor Board, radiation oncologists Dr. Ryan Funk and Dr. Dustin Boothe discuss modern radiopharmaceutical efficacy and tolerability, infrastructure for building a radiopharmaceutical program and its regulatory hurdles, and the future of the field—personalized dosimetry and combination therapies. This podcast is sponsored by Siemens Healthineers: na2.hubs.ly/H04cSxf0 Listen to the full discussion here: na2.hubs.ly/H04d04X0 #Oncology #Radiopharmaceuticals #RadiopharmaceuticalTherapeutics #RadiationOncology #SiemensHealthineers #ARIACOREforTheranostics #CommunityTheranostics #ONC50

We just wrapped HCC Creator Weekend in New Orleans - and it did NOT disappoint! BackTable’s Hepatocellular Carcinoma (HCC) Creator Weekend brought together leading voices for exclusive in-studio sessions you’ll want to hear. All-new HCC episodes are on the way - and trust us, you won’t want to miss these. 🎙️ #Oncology #MedOnc #HCC #MultidisciplinaryCare #TumorBoard

Inflammatory breast cancer (IBC) rarely presents with a lump. Instead, it often appears as redness, swelling, skin thickening – often mistaken as mastitis or infection. In this episode of BackTable Tumor Board, Dr. Lindsay Peterson and Dr. Bora Lim discuss typical and atypical IBC presentations, practical diagnostic workups, evolving therapies, and how complementary tools can guide ongoing surveillance. Early recognition changes trajectories and saves lives. Listen in and share with a colleague: na2.hubs.ly/H03VZx40 #BreastCancer #IBC #Oncology #TumorBoard #ClinicalTrials #MDAnderson #49

Intermediate-risk NMIBC management is evolving - are you up to date? Our latest CME activity is now live on FreeCME, designed to support real-world decision-making across urology and oncology. This 2-hour course explores: • Risk stratification & diagnostic precision • Strategies for BCG-refractory disease • Emerging and alternative therapies • Multidisciplinary care coordination • And More Start learning today on FreeCME: na2.hubs.ly/H03QTVM0 #BladderCancer #NMIBC #Urology #Oncology #CME #MedEd